Related Experiment Videos
Clinical use of the long acting somatostatin analogue octreotide in pediatrics
M T Tauber1, A G Harris, P Rochiccioli
1Department of Paediatric Endocrinology, CHU Purpan, Toulouse, France.
Insights
Preliminary data suggest octreotide (Sandostatin) effectively treats pediatric hyperinsulinemic conditions, protecting brain function and potentially reducing mortality. Long-term use may prevent pancreatectomy and manage secretory diarrhea.
Area of Science:
- Pediatric Endocrinology
- Pharmacology
Background:
- Nesidioblastosis and hyperinsulinemic conditions present significant pediatric health challenges.
- Current treatments may have limitations, necessitating alternative therapeutic options.
Purpose of the Study:
- To report preliminary data on the use of octreotide (Sandostatin) in pediatric patients.
- To evaluate octreotide's efficacy in managing hyperinsulinemic conditions, secretory diarrhea, and familial tall stature.
Main Methods:
- Administration of long-acting somatostatin analog octreotide.
- Observation of blood glucose levels, mortality rates, and treatment outcomes.
- Assessment of impact on height velocity and final height.
Main Results:
- Octreotide rapidly increases blood glucose, even in non-responders to diazoxide.
- Potential to avoid pancreatectomy with long-term octreotide use.
- Effective symptomatic treatment for secretory diarrhea and familial tall stature.
Conclusions:
- Octreotide demonstrates promise in pediatric hyperinsulinemic conditions, secretory diarrhea, and tall stature.
- Individual patient response to octreotide therapy requires thorough investigation.
Abstract:
Preliminary data of the use of the long-acting somatostatin analog octreotide (Sandostatin) in pediatrics are reported. In nesidioblastosis and other hyperinsulinemic conditions, timely treatment with octreotide can protect cerebral function and may reduce mortality. The acute use of octreotide produces prompt elevation of blood glucose, even in patients who fail to respond to diazoxide. In addition, it may be possible to avoid the need for partial or subtotal pancreatectomy by the long-term use of octreotide. As in adults, octreotide should find a place in the symptomatic treatment of secretory diarrhea, notably the watery diarrhea hypokalemia-achlorhydria complex and pancreatic cholera syndrome. Octreotide has been shown to be effective in the treatment of familial tall stature by reducing height velocity and final height. Responses to octreotide therapy vary and the individual responsiveness must be extensively studied.